Navigation Links
Enox Biopharma, Inc. Will Be Granted its Foundation Patent

VANCOUVER, British Columbia, Aug. 22, 2011 /PRNewswire/ -- Enox Biopharma, Inc., a leader in the development of innovative solutions for infections associated with medical devices, today announced that it has received a notice of allowance from the US Patent Office that its patent application entitled "Antimicrobial Gas-Releasing Ear Drainage Tubes" has been approved and a patent will granted.

This patent was the first applied for by Enox and is the foundation patent of the company. The notice of allowance for this patent underscores the novelty of Enox's technology which utilizes nitric oxide gas embedded into polymers as an antimicrobial to prevent hospital acquired infections. Nitric oxide is well recognized as an ideal antimicrobial agent that is highly effective yet free from the drug resistance issues that have resulted from excessive antibiotic use. Additional patent applications, which are under review in the United States and in countries around the world, expand the use of antimicrobial gas releasing technology to virtually any polymer-based medical device.

"This is a very significant patent for Enox. Not only does it solidify our intellectual property portfolio, it is rigorous external validation of our technology being the first of its kind. With our foundation patent issued, the probability of our other intellectual property applications being successful is increased," stated Enox CEO, John Rewcastle, Ph.D. "Nitric oxide emitting medical devices have a unique potential to reduce hospital acquired infections which are a global problem costing tens of billions of dollars annually. The issuance of this patent further ensures Enox is the only company that can create such devices."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. NO is also an effective vasodilator which can lead to accelerated wound healing. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D., CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax

SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference
2. Enox Biopharma, Inc. Will Be Granted a Patent for the Delivery of Therapeutic Agents From Within Medical Devices
3. PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015
4. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
5. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
6. Plato BioPharma, Inc Appoints New Board Member
7. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
8. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
9. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... set to go online. The potential to save costs, ... vast and far from fully exploited as yet. Here, ... health records, either via mobile tablet or directly at ... --> ) -->      ...
(Date:11/27/2015)... 2015 ... "2016 Global Tumor Marker Testing Market: ... Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, ... their offering. --> ) ... "2016 Global Tumor Marker Testing Market: Supplier ...
(Date:11/26/2015)... the Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... the Netherlands has found that immunotherapy can ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the November 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, ... of 750,000. The digital component is distributed nationally, through a vast social media ...
(Date:11/27/2015)... ... 2015 , ... Consistent with the Radiology Business Management ... Radiology Marketing Programs meeting will showcase some of the best 2015 radiology ... Palace in Las Vegas with a pre-conference session on a collaborative approach for ...
(Date:11/27/2015)... Minn. (PRWEB) , ... November 27, 2015 , ... ... start failing. Secura Consultants has prided itself for not only fulfilling the needs ... income protection solutions at an affordable price and providing top-tier customer service. However, ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women ... healthcare organizations in the country. They have overseen financial turnarounds, shown commitment to ... the healthcare industry as a whole through their advocacy and professional efforts. , ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer ... incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product ... Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not only ...
Breaking Medicine News(10 mins):